Reneo Pharmaceuticals appoints Roshawn Blunt as Class I director

OnKure Therapeutics, Inc.

Roshawn Blunt appointed as Class I director effective August 2, 2022, term expiring at 2025 annual meeting.
She will receive $40,000 annual cash retainer and an initial option grant of 35,000 shares vesting over three years.
Further annual option grants of 17,500 shares, vesting by next annual meeting, with full acceleration on change in control.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Roshawn Blunt

Class I Director

OKUR · OnKure Therapeutics, Inc.

Effective: 2022-08-02
Filed: August 2, 2022, 7:59 PM ET

appointed Roshawn Blunt as a Class I director of the Company, with a term of office expiring at the 2025 annual meeting of stockholders.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Roshawn Blunt was appointed as Class I Director at OnKure Therapeutics, Inc..

Action: appointed
Role: Class I Director

Exact text from the filing

appointed Roshawn Blunt as a Class I director of the Company, with a term of office expiring at the 2025 annual meeting of stockholders.

View on SEC.gov

OnKure Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-22-209391

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.